$AXP

JPMorgan's October Stock Picks Diversify Across Financials, Biotech, and Energy

JPMorgan released its October stock picks, adding American Express (AXP), Thermo Fisher Scientific (TMO), and Liberty Energy (LBRT) to its 'overweight' list. AXP is seen as a value play despite a 18% YTD decline, while TMO and LBRT are growth picks due to strong sector trends. The bank advises diversification across sectors for Q4.

Original reporting
Published Oct 5, 2026, 5:55 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 6:43 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$AXP
Bullish
medium confidence
Mentioned
$AXP · $TMO · $LBRT
Relevance
7/10
AlphAI data visualization · based on finance.biggo.com
Decision brief

The 30-second read

$AXPBullishMed
01

Why it matters

The recommendations provide fresh analyst endorsement that could drive short‑term buying interest.

02

Market read

Analyst upgrades can prompt immediate portfolio adjustments, especially for the highlighted stocks.

03

What to watch

Potential headwinds for consumer spending could limit AXP upside; regulatory risks may affect TMO.

Relevance 7/10Novelty 7/10Timing: today

Background

JPMorgan released its October stock ideas, highlighting new overweight positions across three sectors.

Company-level read

Ticker impact

$AXPBullishMedium confidence
Context

JPMorgan added American Express as a new value pick in its October stock list.

Expected impact

likely upside as investors consider the value rating.

Evidence & confidence

The recommendation is fresh and highlights dividend yield and buyback support.

$TMOBullishMedium confidence
Context

Thermo Fisher Scientific was newly listed as a growth pick by JPMorgan.

Expected impact

potential price lift from perceived growth catalysts.

Evidence & confidence

Analyst cites federal reshoring policy and AI adoption as upside drivers.

$LBRTBullishMedium confidence
Context

Liberty Energy was added as a growth pick, tied to AI data‑center power demand.

Expected impact

likely upward pressure as the AI‑driven power narrative gains traction.

Evidence & confidence

Analyst highlights structural tightness in behind‑the‑meter power markets.

Market effects

The picks signal a rotation toward diversified financial, life‑sciences, and energy exposure.

U.S. investors may rebalance portfolios toward these sectors amid mixed market performance.

Broadly reflects JPMorgan's view on sector diversification, influencing global equity sentiment.

Counterpoint

Some investors may view the picks as overly optimistic given recent market volatility.

Key entities

  • JPMorgan Chase

    Issuer of the stock recommendation list.

  • American Express

    New value pick.

  • Thermo Fisher Scientific

    New growth pick.

  • Liberty Energy

    New growth pick.

Related articles

$AXPMed

JPMorgan reveals stocks worth buying in October 2026

JPMorgan added five stocks to its Overweight list, highlighting American Express (AXP) as a Value pick, Thermo Fisher (TMO) and Liberty Energy (LBRT) as Growth picks. AXP is down 18-19% YTD but JPMorgan sees steady profits and share buybacks. TMO is up 25% in 3 months, with growth driven by partnerships and AI-powered lab machines. LBRT is up 52% in 12 months, benefiting from AI data center power demands.

$QNTMMed

Quantum BioPharma Taps Thermo Fisher for Lucid-MS Phase 2 Trial in Multiple Sclerosis

Quantum BioPharma (QNTM) has partnered with Thermo Fisher Scientific to begin Phase 2 trials for Lucid-MS, a treatment for progressive multiple sclerosis. The FDA has cleared the trial, which will assess efficacy, safety, and tolerability. Thermo Fisher will provide clinical research services. Success could offer a new treatment option for MS, a condition with limited therapies. Quantum owns 19.84% of Unbuzzd Wellness and receives royalties from it.

$QNTMMedAI 8/10

Quantum BioPharma Advances Multiple Sclerosis Trial with Thermo Fisher Partnership

Quantum BioPharma (QNTM) partnered with Thermo Fisher Scientific to start a Phase 2 trial for Lucid-MS, a treatment for progressive multiple sclerosis. The trial, cleared by the FDA, will assess efficacy, safety, and tolerability. Lucid-MS targets myelin degradation, differing from existing therapies. Quantum owns 19.84% of Unbuzzd Wellness, with royalty agreements in place.

$QNTMMed

Quantum BioPharma Signs Contract with Thermo Fisher Scientific’s Clinical Research Business to Implement Phase 2 Lucid-MS Trial in Multiple Sclerosis

Quantum BioPharma (QNTM) has signed a contract with Thermo Fisher Scientific to implement its Phase 2 clinical trial for Lucid-MS, a treatment for multiple sclerosis. The trial will evaluate the drug's efficacy, safety, and tolerability. Quantum BioPharma received FDA clearance to proceed with the study. The multiple sclerosis market is projected to exceed $38 billion by 2030, according to Grand View Research.